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Summary
 
Polymorphonuclear granulocytes (PMNs) are thought to fulfill their role in host defense prima-
rily via phagocytosis and release of cytotoxic compounds and to be inefficient in antigen pre-
sentation and stimulation of specific T cells. Dendritic cells (DCs), in contrast, are potent anti-
gen-presenting cells with the unique capacity to initiate primary immune responses. We
demonstrate here that highly purified lactoferrin-positive immediate precursors of end-stage
neutrophilic PMN (PMNp) can be reverted in their functional maturation program and driven
to acquire characteristic DC features. Upon culture with the cytokine combination granulo-
cyte/macrophage colony-stimulating factor plus interleukin 4 plus tumor necrosis factor 
 
a
 
,
they develop DC morphology and acquire molecular features characteristic for DCs. These molec-
ular changes include neo-expression of the DC-associated surface molecules cluster of differen-
tiation (CD)1a, CD1b, CD1c, human leukocyte antigen (HLA)-DR, HLA-DQ, CD80, CD86,
CD40, CD54, and CD5, and downregulation of CD15 and CD65s. Additional stimulation
with CD40 ligand induces also expression of CD83 and upregulates CD80, CD86, and HLA-DR.
The neutrophil-derived DCs are potent T cell stimulators in allogeneic, as well as autologous,
mixed lymphocyte reactions (MLRs), whereas freshly isolated neutrophils are completely unable
to do so. In addition, neutrophil-derived DCs are at least 10,000 times more efficient in present-
ing soluble antigen to autologous T cells when compared to freshly isolated monocytes. Also,
in functional terms, these neutrophil-derived DCs thus closely resemble “classical” DC populations.
 
D
 
endritic cells (DCs)
 
1
 
 comprise a heterogeneous popu-
lation of professional APCs with particularly potent T
 
cell immunostimulatory capacity (1). Various subtypes can
be distinguished that differ in location, stage of maturation,
and probably also in their developmental relationship to
other hemopoietic cells (2–4).
At least one developmental pathway giving rise to cells
with DC characteristics seems to be closely linked to the
monocyte/macrophage differentiation system and has re-
cently attracted considerable interest (for review see refer-
ences 2, 3, 5). DCs of this type, when generated from
CD34
 
1
 
 progenitor cells in the presence of GM-CSF and
TNF-
 
a
 
 undergo a transient stage of development charac-
terized by the expression of CD14 and c-fms (M-CSF re-
ceptor) in the absence of CD1. This intermediate stage
CD14
 
1
 
CD1
 
2
 
 cell type has bipotential capacity. Stimula-
tion with M-CSF induces acquisition of macrophage char-
acteristics; in the presence of GM-CSF plus TNF-
 
a
 
 they
give rise to DCs (6, 7).
Similar bipotential capacity has recently also been dem-
onstrated for much further differentiated stages of mono-
cyte/macrophage development, peripheral blood mono-
cytes. Stimulation of blood monocytes with the cytokine
combinations GM-CSF plus IL-4 (8, 9) or GM-CSF plus
IL-13 (10) was found to induce transition to a DC pheno-
type in virtually all monocytes; incubation with GM-CSF
plus TNF-
 
a
 
 in the absence of IL-4 leads to formation of
macrophage-like cells (8, 11, 12). Monocytes thought to be
committed to macrophage development can thus be driven
in one of either two directions. Formation of macrophages
with mainly proinflammatory/phagocytic effector cell charac-
teristics, or generation of DC-like cells with professional
antigen presenting and limited phagocytic capacity.
Apart from DCs, monocyte/macrophages are also closely
related to neutrophil granulocytes. Single cell colony assays
demonstrated that both cell types derive from one and the
 
1
 
Abbreviations used in this paper: 
 
CD, cluster of differentiation; CD40L,
CD40 ligand; CML. chronic myeloid leukemia; DC, dendritic cell; HLA,
human leukocyte antigen; LF, lactoferrin; md-DC, monocyte-derived
DC; MLR, mixed lymphocyte reaction; MPO, myeloperoxidase; PMNp,
PMN granulocyte precursor; rh, recombinant human; TT, tetanus toxoid.
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same bipotent progenitor (CFU-GM; references 13, 14)
that, upon further differentiation, gives rise to the irrevers-
ibly committed monocyte (CFU-M) or granulocyte (CFU-G)
lineage (for review see reference 15).
The first morphologically unequivocally identifiable
stage of neutrophil granulocyte development is the promy-
elocyte. This cell type has already a limited growth capacity
in semisolid culture systems (16) but can, at least with cer-
tain differentiation inducing agents, still be driven to ac-
quire either granulocytic or monocytic features (17, 18).
The later stages of neutrophil differentiation (myelo-
cytes, metamyelocytes, band cells, and end-stage PMNs)
are characterized by the presence of specific neutrophilic
granules in their cytoplasm and by the expression of the
specific granule marker molecule lactoferrin (LF; references
19–21). These late LF
 
1
 
 stages of neutrophil differentiation
have so far been considered as being irreversibly fixed in
their maturation program towards end-stage PMN devel-
opment.
Here we show that such immediate granulocyte precur-
sors of end-stage PMN (PMNp) can still be reprogrammed
and even be driven to acquire the characteristic phenotypic
and functional features of DCs.
 
Materials and Methods
 
Media and Reagents
 
As a culture medium RPMI 1640 supplemented with 2 mM
L-glutamine, 10% FCS, 100 U/ml penicillin, and 100 
 
m
 
g/ml
streptomycin was used. Recombinant human (rh)GM-CSF and
rhIL-4 were provided by the Novartis Forschungs Institut (No-
vartis Research Institute, Vienna, Austria). RhTNF-
 
a
 
 was a gift
of G.R. Adolf (Ernst Boehringer Institut für Arzneimittelfor-
schung, Vienna, Austria). RhG-CSF was obtained from Hoff-
mann–La Roche (Basel, Switzerland). Trimeric human cluster of
differentiation (CD)40 ligand fusion protein (CD40L) was pro-
vided by S.D. Lyman (Immunex Corp., Seattle, WA).
 
Antibodies
 
The following murine mAbs used in the study were generated
in our laboratory: VIAP (calf intestine alkaline phosphatase spe-
cific) nonbinding control, CD1a mAb VIT6b, CD1b mAb 7C4,
CD1c mAb 10C3, CD5 mAb 5D7, CD14 mAb VIM13, CD65s
mAb VIM2, CD33 mAb 4D3, CD15 mAb VIM16, and CD16
mAb 8B3. The human leukocyte antigen (HLA)-DR mAb L243
was obtained from American Type Culture Collection (Rock-
ville, MD). The mAbs specific for HLA-DQ (clone SK10),
CD34 (clone HPCA2), and CD80 (L307) were obtained from
Becton Dickinson (San Jose, CA). The myeloperoxidase (MPO)-
specific mAb H-43-5, the LF-specific mAb 4C5, the mAb
CD117 (c-kit, 95C3), and the mAb CD3 (UCHT-1) were ob-
tained from An der Grub (Bio Forschungs GmbH, Kaumberg,
Austria). CD86 mAb (IT2.2) was from PharMingen (San Diego,
CA). The CD83 mAb (HB15a) was obtained from Immunotech
Inc. (Marseille, France). The mAb specific for CD19 (SJ25-C1)
was obtained from Caltag (Burlingame, CA). CD40 mAb (G28-
5) was a gift from J.A. Ledbetter (Seattle, WA). Ki-67 mAb
(MIB-1) was obtained from Dianova (Hamburg, Germany).
 
Cells
 
PBMCs were isolated by standard density gradient centrifuga-
tion with Ficoll-Paque (Pharmacia, Uppsala, Sweden) from hep-
arinized whole blood of patients with chronic myeloid leukemia
(CML) and of patients with leukocytosis and left shifted differen-
tial blood counts due to bacterial infections or G-CSF treatment.
CML diagnosis was made on the basis of hematological findings
and the presence of the Philadelphia chromosome. Three patients
were newly diagnosed, one patient had for 10 d received treat-
ment with hydroxyurea, and one patient was in accelerated phase
and previously untreated. Mean leukocyte counts in CML pa-
tients were 131,000/
 
m
 
l (range 91,000–153,000). The nonleuke-
mic peripheral blood samples were obtained from two patients
with pneumonia, one patient suffering from osteomyelitis and
from two donors (one patient with high-grade non-Hodgkin
lymphoma in complete remission and one normal donor) who
received G-CSF treatment at a dose of 10 
 
m
 
g/kg of body weight
on four consecutive days (mean leukocyte count 24,900/
 
m
 
l,
range 16,500–28,000).
 
Cell Separation
 
PBMCs were washed twice in PBS supplemented with 5 mM
EDTA and 0.5% human serum albumin. Subsequently, VIM16
 
1
 
(CD15) cells were separated by high gradient magnetic sorting
using the 
 
VARIO
 
MACS technique (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany). This method has been described
in detail elsewhere (22). mAb VIM16 (clone CD15-10C4) was
selected for granulocyte isolation from our panel of CD15 mAbs
(23) since it selectively binds to normal and malignant granulo-
cytes, but neither to monocytes (23) nor to immature leukemic
blast cells, with the exception of very rare cases (W. Knapp, un-
published observation). In brief, PBMCs were incubated with
saturating concentrations of biotinylated VIM16 mAb for 15 min
on ice, washed in PBS containing 5 mM EDTA and 0.5% human
serum albumin, and incubated, thereafter, with colloidal super-
paramagnetic microbeads conjugated with streptavidin for 10 min
at 4
 
8
 
C. Labeled and positively enriched cells were eluted from
magnetic columns by removal of columns from the magnetic de-
vice. To evaluate the efficiency of the cell separation, aliquots of
the positively enriched cell fraction were stained and analyzed by
flow cytometry.
Highly purified T cells (purity 
 
.
 
97%) were obtained by deple-
tion of all non–T cells by the above described method using
mAbs against CD14, CD16, CD19, and HLA class II. Monocytes
were enriched essentially as described before (11) by using the bi-
otinylated CD14 mAb VIM13 (purity 
 
.
 
95%).
 
Cultivation of Cells
 
Isolated PMNp cells were cultured at a cell density of 5 
 
3
 
 10
 
5
 
cells/ml in standard culture flasks (Costar, Cambridge, MA) in
RPMI 1640/10% FCS medium at 37
 
8
 
C in a humidified CO
 
2
 
containing atmosphere. For induction of cell differentiation, the
culture medium was supplemented with rhGM-CSF (550 IU/ml),
rhIL-4 (100 IU/ml) and rhTNF-
 
a
 
 (50 IU/ml). During culture,
cells were not replenished with cytokines. Two PMNp cell sam-
ples were cultured in parallel with G-CSF at 1,000 IU/ml. For
induction of “terminal” maturation (8, 24), GM-CSF plus IL-4
and TNF-
 
a
 
 cultured cells were recovered on day 7, washed, and
recultured for a further 2 d with CD40L (200 ng/ml) plus GM-
CSF (550 IU/ml) supplemented culture medium. 
1021
 
Oehler et al.
Monocyte-derived DCs (md-DCs) were generated in the
presence of GM-CSF plus IL-4 as described previously (11).
 
Morphological Cell Analysis
 
Freshly isolated VIM16
 
1
 
 cells and cells cultured for 1–13 d
were centrifuged onto microscope slides using a centrifuge
(Cytospin-2; Shandon Southern Products, Astmoor, UK), stained
with May-Grünwald-Giemsa solution and analyzed by light mi-
croscopy on a Leitz Aristoplan microscope (Wetzlar, Germany).
 
Immunofluorescence Staining Procedures
 
Membrane Staining.
 
For membrane staining, 50 
 
m
 
l of cells (1
 
3
 
 10
 
7
 
/ml) were incubated for 15 min at 0–4
 
8
 
C with conjugated
FITC, PE, or unconjugated mAb. For staining using unconju-
gated mAbs, FITC-conjugated F(ab
 
9
 
)
 
2
 
 fragments of sheep anti–
mouse immunoglobulin antibodies (An der Grub), were used as a
second step reagent as described (25).
 
Intracellular Staining.
 
For suspension staining of intracellular
antigens, we used the reagent combination Fix & Perm (An der
Grub) as described previously (26). In brief, cells are first fixed in
fixation medium for 15 min at room temperature and after one
washing step, cells are resuspended and mixed with permeabiliza-
tion medium plus fluorochrome (FITC or PE) -labeled antibody.
After a further incubation for 15 min at room temperature, cells
are washed again and analyzed.
 
Combined Membrane/intracellular Staining.
 
For combined staining
of membrane and intracellular molecules, cells were first stained
with FITC-conjugated mAb as described above, and stained
thereafter as described for intracellular staining.
 
Flow Cytometry.
 
Flow cytometric analyses were performed
using a FACScan
 
Ò
 
 flow cytometer.
 
Cell Cycle Analysis
 
Staining procedures were performed with slight modifications
as described previously (27). In brief, cells were centrifuged onto
glass slides and fixed with 1% paraformaldehyde in PBS for 2 min
at ambient temperature, followed by permeabilization with pure
methanol for 10 min at 
 
2
 
20
 
8
 
C. For staining, individual slides
were incubated either with FITC-conjugated Ki-67 mAb or with
the FITC-labeled isotype-matched nonbinding control mAb
VIAP for 1 h at room temperature. The fluorescence signal was
improved by using FITC-conjugated goat anti–mouse immuno-
globulin antibodies (An der Grub) as a second step reagent. After
two washes, slides were mounted with glycerol and analyzed on a
microscope (Leitz Aristoplan; Wetzlar, Germany).
 
Proliferation Assays
 
A constant number of 10
 
5
 
 autologous or allogeneic, highly pu-
rified T cells were incubated with graded numbers of irradiated
(3,000 rad, 
 
137
 
Cs source) freshly isolated PMNp or monocytes
and cultured PMNp or monocytes. Experiments were performed
in 96-well cell culture plates in RPMI 1640 medium supplemented
with 10% human serum. Proliferation of T cells was monitored
by measuring [methyl-
 
3
 
H]TdR uptake (Amersham, Buckingham-
shire, UK) incorporation on day 4 of culture. Cells were harvested
18 h later and radioactivity was determined on a Topcount micro-
plate scintillation counter (Packard Instrument Co., Meriden, CT).
 
Tetanus Toxoid Presentation Assay
 
Presentation of tetanus toxoid (TT; Connaught Laboratories,
Willowdale, Ontario, Canada) by neutrophil-derived DCs or
monocytes to autologous T cells was performed by coculturing
10
 
4
 
 DCs or monocytes with a constant number of 10
 
5
 
 highly pu-
rified T cells. The cultures were set up in the presence of increasing
amounts of TT. Proliferation was measured by [
 
3
 
H]TdR uptake
on day 7 of culture. Background counts due to ongoing autologous
mixed lymphocyte reaction (MLR) without TT were subtracted.
 
Results
 
Purification of Neutrophil Granulocytes
 
Neutrophilic granulocytes were isolated from PBMC
fractions of blood samples with high neutrophil counts and
 
Table 1.
 
Morphological, Cytochemical, and Molecular Characterization of Freshly Isolated VIM16
 
1
 
 Cells
 
Patient
No. Diagnosis
Differential blood count
(morphological)
Esterase
(% positive)
Expression of surface/cytoplasmatic molecules
(percent positive)
PMN BC MMC MC PMC VIM16 MPO LF CD14 CD16 CD65s CD34 CD117 HLA-DR
1 CML 0 41 34 14 11 0 94 97 62 0 48 97 0 0 1
2 CML 0 52 26 13 8 0 99 99 57 2 n.t. 98 0 0 0
3 CML 0 97 2 1 0 0 99 99 98 0 92 99 0 0 0
4 CML 0 90 6 4 0 0 97 98 97 0 90 98 0 0 0
5 CML 0 92 7 3 0 0 97 100 96 0 75 98 0 0 0
6 Pn. 0 96 3 0 0 0 99 98 98 0 80 99 0 0 0
7 Pn. 2 94 0 0 0 1 95 96 95 1 82 97 0 0 1
8 Om. 9 90 1 0 0 0 100 100 99 0 99 99 0 0 0
9 N.D. 0 90 6 2 0 1 99 99 96 2 83 99 0 n.t. 1
10 NHL 0 91 7 1 0 0 99 99 98 0 84 99 0 n.t. 0
 
BC
 
, band cells; 
 
MMC
 
, metamyelocytes; 
 
MC
 
, myelocytes; 
 
PMC
 
, promyelocytes; 
 
CML
 
, chronic myeloid leukemia; 
 
Pn
 
., pneumonia; 
 
Om
 
. osteomy-
elitis; 
 
N.D
 
., normal donor; 
 
NHL
 
, non-Hodgkin lymphoma, 
 
n.t.
 
, not tested. 
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outspoken shifts to the left (five patients with CML, patient
No. 1–5; three patients with bacterial infections, patient
No. 6–8; two donors treated with G-CSF, patient No. 9
and 10) using a magnetic bead-based positive immunose-
lection procedure and the mAb VIM16 (CD15, Lewis
 
x
 
 an-
tigen; see Materials and Methods).
The obtained preparations of mAb VIM16-reactive cells
were strongly enriched for immediate PMNp and included
band cells, metamyelocytes, and myelocytes (Table 1). The
achieved purity of neutrophil granulocytes belonging to
the maturation compartment of myeloid differentiation is
exemplified also by the degree of cells expressing LF, a
highly reliable marker molecule for late-stage neutrophil
development (20). Of particular importance to our studies,
the isolated PMNp preparations contained in all instances
no or very few (
 
,
 
2%) monocytes as evaluated by morphol-
ogy, cytochemistry and CD14 expression (Table 1) and
they were virtually free of immature CD34
 
1
 
, CD117
 
1
 
,
and/or HLA-DR
 
1
 
 progenitor cells (Table 1). In three of
the five CML samples tested (patients No. 3–5) the propor-
tions of LF
 
1
 
 cells were particularly high (97, 96, and 98%,
respectively), which makes these samples particularly infor-
mative. Also the isolated PMNp samples from nonleuke-
mic patients were highly enriched for LF
 
1
 
 cells (95–99%,
the remaining cells were mainly CD3
 
1
 
 T cells, data not
shown) and contained almost exclusively band cells (Table
1). Two such cell samples (from patient No. 9 and 10)
were cultivated in medium supplemented with G-CSF
(1,000 IU/ml) to study their maturation potential. Within
Figure 2. Total cell number
and number of Ki-671 cells
upon culture of PMNp from
CML (A) and nonleukemic cell
samples (B). PMNp were culti-
vated in RPMI 1640 plus 10%
FCS with GM-CSF plus IL-4
plus TNF-a. Total cell number
(black circles) and number of cells
reactive with the FITC-conju-
gated mAb Ki-67 (open circles)
were evaluated at indicated time
points. The figure shows mean
values of independently per-
formed experiments with cell samples from patient No. 3, 4, and 5 (A)
and patient No. 6, 7, and 8 (B).
Figure 1. Appearance of cell preparations in liquid culture and upon cytochemical staining. Characteristic phase contrast morphology of freshly isolated
PMNp showing a homogeneous population of equally sized, round cells (A), and after 9 d of culture with medium containing GM-CSF plus IL-4 plus
TNF-a, cells uniformly impose with widespread projections and irregular cell forms (B). Cells cultured for 7 d with GM-CSF plus IL-4 plus TNF-a and
then stimulated with CD40L in the presence of GM-CSF develop long dendrites and form numerous small clusters within 24 h (C). Representative pho-
tographs of May-Grünwald-Giemsa–stained cytospin preparations: PMNp cultured in G-CSF–supplemented medium for 3 d exhibit polysegmented nu-
clei typical for end-stage PMNs (D). E shows freshly isolated PMNp with uniformly rod-shaped nuclei. Between days 3 (F) and 6 (G), cultured cells
develop small nonlobulated round nuclei whereas cell size increases. After a culture period of 9 d, the vast majority of GM-CSF plus IL-4 plus TNF-a–
treated cells show widespread cytoplasmic projections (H). Most cells contain numerous dense granules (G and H). 
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2–3 d, these late-stage PMN precursors almost uniformly
(
 
.
 
80%) developed polysegmented nuclei typical for end-
stage PMNs (Fig. 1 
 
D
 
)
 
Morphological Changes and Growth Characteristics during 
Culture
 
Freshly isolated PMNp represented a homogeneous
population of equally sized, round cells (Fig. 1 
 
A
 
). In
cytospin preparations, most of their nuclei imposed rod-
shaped with plague-shaped chromatin (Fig. 1 
 
E
 
). Upon
culture in GM-CSF plus IL-4 plus TNF-
 
a
 
 supplemented
medium, in contrast to G-CSF (Fig. 1 
 
D
 
), the isolated
PMNp from 10 donors analyzed in this study uniformly
grew in size and developed, relative to the cytoplasmic
proportion, small nonlobulated round nuclei (Fig. 1 
 
E–H
 
).
The cytoplasm imposed with widespread projections and
most cultivated cells contained numerous dense granules
(Fig. 1, 
 
G
 
 and 
 
H
 
). During culture, cells showed little or no
tendencies to adhere to the culture plate and formed only a
few aggregates (Fig. 1 
 
B
 
).
To test for potential mitotic activity, cells were analyzed
daily during culture for expression of the proliferation-
associated nuclear Ag Ki-67 and incorporation of [methyl-
 
3
 
H]TdR. In PMNp samples obtained from CML patients,
only at late stages of culture (from day 8 onwards) and also
here only in small proportions of cells (6–8%) Ki-67 ex-
pression, known to be present in all phases of the cell cycle
with the exception of G0 and early G1, could be detected
(Fig. 2). In addition, the number of cells in culture slightly
decreased (mean: 16.5% decrease). At variance, only in one
of the three tested nonleukemic VIM16
 
1
 
 cell samples, Ki-
67 expression (7%) could be detected at day two of culture,
correlating with the otherwise undetectable [methyl-
 
3
 
H]TdR
uptake (data not shown). In contrast to the leukemic cells,
a significant cell loss (40–50%) occurred. The moderate
proliferative activity detected in some of the cultured cell
samples may represent dividing myelocytes, known to have
limited proliferative capacity (16, 28).
Thus, the vast majority of cells recovered and analyzed
between days 9 and 11 obviously represent in vitro differ-
entiated nonreplicating cells rather than a replicating subset
of input cells.
 
Phenotypic Changes
 
Surface molecules.
 
Concomitant with the observed mor-
phological changes, profound molecular alterations emerge
upon cultivation of purified PMNp. As can be seen from
the staining patterns (FACS
 
Ò
 
 profiles) shown in Fig. 3, the
first molecular changes to be observed are neo-expression
Figure 3. Expression kinetics of surface and cytoplasmic molecules
upon cultivation of PMNp. The figure shows overlay histogramms of
freshly isolated PMNp or PMNp cultured with GM-CSF plus IL-4 plus
TNF-a for indicated time periods. Single histogramm profiles of indi-
cated markers are shown of one representative experiment (patient No. 8).
Open profiles, staining pattern with a nonbinding control antibody; black
profiles, staining pattern with mAbs of the indicated specificity. Abscissa,
fluorescence intensity (log 10 scale); ordinate, the respective cell number.
Figure 4. Expression pattern
of neo-expressed or downregu-
lated differentiation molecules
on freshly isolated or cultured
PMNp. Expression pattern of
differentiation molecules of freshly
isolated PMNp (left) and after
cultivation in GM-CSF plus IL-4
plus TNF-a (right) was analyzed
by flow cytometry. Binding of
mAbs to individual cell samples
is represented as percent positive
cells (mean values 6 SD) calcu-
lated from three separate experi-
ments performed with cell sam-
ples derived from patient No. 3,
4, and 5.
 1024 Neutrophil-derived Dendritic Cells
of HLA-DR, HLA-DQ, CD40, and CD54. Expression of
HLA-DR and CD40 are detected already on day 1 of cul-
ture (3–13% and 30–40% positive cells, respectively) and
the number of positive cells constantly increased (day 2 5–40
and 38–75%, respectively). With prolonged culture (days
6–9), several additional DC-related molecules become sur-
face expressed. Among them, all tested members of the
CD1 family (CD1a, b, and c), CD80 (B7-1), CD86 (B7-2),
and CD5 are observed (Figs. 3 and 4). In parallel, the poly-
N-acetyllactosamine structures CD65s and CD15 are
downregulated (Figs. 3 and 4), as previously reported for
GM-CSF plus IL-4 cultured monocytes (11).
Intracellular Antigens. Interestingly, upon differentiation
of neutrophils during culture, LF content steadily decreased
(Fig. 3). This decrease occurred virtually in parallel to a
steady increase of CD40 expression (Fig. 3). At an interme-
diate time point (between days 2 and 6), considerable num-
bers of cultured cells coexpressed the neutrophil secondary
granule protein LF with the costimulatory surface molecule
CD40 (Fig. 5). The granulomonocyte-restricted primary
granule molecule MPO also decreased upon differentia-
tion, but remained detectable even after prolonged culture
period.
CD40L-induced Maturation
The phenotype of cells generated as described above in
GM-CSF plus IL-4 and TNF-a–containing medium is
reminiscent of immature DCs. We, therefore, attempted to
differentiate these cells to mature DCs. For this purpose,
GM-CSF plus IL-4 and TNF-a cultured PMNp were har-
vested on day 7, washed, and then replated in CD40L (200
ng/ml) plus GM-CSF supplemented medium. Under these
conditions, PMNp-derived DCs acquired the characteristic
features of mature DCs, as has been described before for
DCs derived from CD341 cells (24) and monocytes (8).
Surface expression density of HLA-DR homogeneously
increased, the costimulatory molecules CD80 and CD86
were significantly upregulated, and clearcut induction of
the DC maturation marker CD83 occurred (Fig. 6). When
these cells, after 48 h of culture with CD40L plus GM-CSF
were washed and replated in medium alone, they remained
viable and expression of CD80, CD86, CD83, CD40, and
HLA-DR was maintained for at least 4 d (data not shown).
Also in morphological terms, treatment with CD40L
plus GM-CSF had a profound impact. Within 24 h, CD40L-
treated cells developed long dendrites and formed typical
small clusters as has been reported before for DCs derived
from CD341 cells (24; Fig. 1 C).
Functional Changes
Potent induction of primary MLR responses is a charac-
teristic functional feature of DCs. We, therefore, compared
Figure 5. PMNp cultured with GM-CSF plus IL-4 plus TNF-a differ-
entiate into CD40-positive cells and loose LF content. PMNp either
freshly isolated or cultured were analyzed at the indicated time points.
Results are shown as two parameter dot plots. For staining, a directly la-
beled CD40 mAb (FITC conjugated) and a LF-specific mAb (PE conju-
gated) were used. As a negative control, nonbinding isotype-matched
mAbs were applied. Markers were set according to the fluorescence char-
acteristics of cells incubated with negative control mAbs.
Figure 6. CD40L upregulates
costimulatory molecules and in-
duces CD83 antigen expression.
Expression patterns of PMNp
(patient No. 9) on day 9 that
were either cultured with GM-
CSF plus IL-4 plus TNF-a or
PMNp that were replated on day
7 and cultured for a further 2 d
in the presence of CD40L plus
GM-CSF. Open profiles depict
staining pattern with a nonbind-
ing control antibody. Gray pro-
files, PMNp cultured with GM-
CSF plus IL-4 plus TNF-a; open
profiles with thick lines, staining
pattern of PMNp cultured with
CD40L plus GM-CSF with
mAbs of the indicated specificity.1025 Oehler et al.
the allostimulatory capacity of both the in vitro–generated
cell populations and the freshly isolated cells by using
highly purified T cells as responder cells.
Fig. 7 A shows a representative experiment comparing
freshly isolated PMNp with PMNp cultured in the cyto-
kine cocktail GM-CSF plus IL-4 and TNF-a for different
time periods. Freshly isolated PMNp do not induce any al-
logenic T cell proliferation even at the highest stimulator
cell numbers tested (up to 2 3 105, data not shown). Upon
cultivation, the ability of these cells to stimulate T cells
constantly increased. A clear [methyl-3H]TdR incorpora-
tion into T cells is already detected at higher stimulator cell
counts after 2 d of culture. Upon further cultivation and in
perfect correlation with increased expression of MHC class
II and CD40 molecules (see Fig. 3) and appearance of the
costimulatory molecules CD80 and CD86 (approximately
days 6–8), cultured cells developed toward highly potent T
cell stimulatory cells (Fig. 7 A).
As shown in Fig. 7 B, the allogenic T cell stimulatory ca-
pacity of PMNp cultured for 9 d with GM-CSF plus IL-4
and TNF-a is virtually identical to the stimulatory capacity
of md-DCs. Also shown in Fig. 7 is the markedly increased
T cell stimulatory capacity of CD40L-treated neutrophil-
derived DCs. These cells were first cultured for 7 d with
GM-CSF plus IL-4 and TNF-a and then for the last 2 d of
the 9-d culture period with CD40L plus GM-CSF. As few
as 50 of these CD40L-treated cells were sufficient to in-
duce substantial T cell responses (52,000 disintegrations/
min with 105 responder T cells in the experiment shown in
Fig. 7 B). PMNp cultured for 9 d with GM-CSF plus IL-4
and TNF-a, in contrast to freshly isolated blood mono-
cytes, were also highly effective to stimulate autologous T
cells (Fig. 7 C).
To test the capacity of cultured PMNp for presentation
of soluble antigen, we evaluated these GM-CSF plus IL-4
and TNF-a cultured cells also for their efficiency to
present TT to autologous highly purified T cells. As shown
in Fig. 7 D, cultured PMNp were approximately four logs
more efficient APC as compared to autologous monocytes.
Discussion
Neutrophil PMNs are the most abundant white blood
cells and comprise about two thirds of all leukocytes in pe-
ripheral blood. In inflammatory conditions, the production
of PMNs further increases and also “young forms” repre-
senting the immediate precursors of end-stage PMNs (band
cells, metamyelocytes, and myelocytes) are released from
bone marrow and can be found in blood and tissue (shift to
the left; reference 29). Neutrophil granulocytes are the first
phagocytes to reach inflamed tissues and play a critical role
in phagocytosis and destruction of invading pathogens (30–
32). Unlike monocytes/macrophages, the second major
phagocyte population, and in contrast to professional anti-
gen-presenting DCs, neutrophil granulocytes are consid-
ered as being highly inefficient in presenting antigenic ma-
terial to T cells and to induce T cell activation. They
normally do not express antigen presenting MHC class II
molecules and they lack signal 2 providing costimulatory
molecules (33, 34).
Here we demonstrate that the immediate PMNp charac-
terized by the presence of specific neutrophilic granules in
the cytoplasm and the expression of LF can be drastically
shifted in their maturation program. By simply culturing
them with selected cytokines (GM-CSF plus IL-4 plus
TNF-a), they can be driven to acquire virtually all of the
characteristic features of professional APCs.
The combination of these three cytokines seems to be
critical. With GM-CSF plus IL-4 alone, shown before to
be efficient in driving monocytes to acquire DC character-
istics (8, 11), we observed with PMNp in a preliminary se-
ries of experiments only limited differentiation along the
DC axis (data not shown).
PMNp cultured with GM-CSF plus IL-4 and TNF-a
first start to express the MHC class II molecules HLA-DR
and HLA-DQ and the accessory molecules CD40 and in-
Figure 7. T cell stimulatory capacity of PMNp-derived DCs. (A) 105
allogeneic highly purified T cells were incubated with graded numbers of
irradiated, either freshly isolated PMNp (day 0) or cells cultured with
GM-CSF plus IL-4 and TNF-a for 2, 5, and 9 d, respectively. Prolifera-
tion of T cells was monitored in all instances by adding [3H]TdR to indi-
vidual cultures on day 4 of culture followed by measuring incorporated
radioactivity 18 h later. Degree of proliferation is indicated as disintegra-
tions per minute 3 103 on the ordinate. The representative experiment
shown here was done with patient No. 3. (B) 105 allogeneic highly puri-
fied T cells were incubated with graded numbers of GM-CSF plus IL-4
and TNF-a cultured PMNp (PMNp day 9), with md-DCs, or with
PMNp that were cultured for 7 d with GM-CSF plus IL-4 and TNF-a
and then replated and cultured for 48 h with CD40L plus GM-CSF
(PMNp day 9 [CD40L]). The representative experiment shown here was
done with patient No. 9.(C) 105 autologous highly purified T cells were
incubated with graded numbers of cultured PMNp (day 9) or highly puri-
fied autologous monocytes. (D) Presentation of TT by PMNp cultured
for 9 d to autologous T cells was performed by coculturing 104 irradiated
PMNp or 104 irradiated autologous monocytes with 105 T cells. The cul-
tures were set up in the presence of increasing amounts of TT. Prolifera-
tion of T cells as shown in B and C was monitored by adding [methyl-
3H]TdR to individual cultures on day 6 of culture followed by measuring
incorporated radioactivity 18 h later. Background counts due to ongoing
autologous MLR without TT were subtracted.1026 Neutrophil-derived Dendritic Cells
tercellular adhesion molecule 1 (ICAM-1; CD54). With pro-
longed culture, several additional APC-related surface mol-
ecules are neo-induced. Among them are the costimulatory
molecules CD80 (B7-1) and CD86 (B7-2), the DC-related
putative antigen-presenting structures CD1a, CD1b, and
CD1c (35), and the scavenger receptor family member CD5
known to be expressed by DCs in addition to T cells (11, 36).
Change of medium at day 7 with culturing cells for the last
2 d in the presence of CD40L and GM-CSF induces an even
further differentiated phenotype (Fig. 6). Cells cultured in
that way exhibit significant CD83 expression and upregulated
surface expression of HLA-DR and costimulatory molecules
CD80 and CD86. Thus, neutrophil-derived DCs react to
CD40L stimulation also, as has been reported before for he-
mopoietic progenitor cell and monocyte–derived DCs (8, 24).
Concurrent with these molecular alterations, cultured
PMNp also acquired functional features highly reminiscent
of professional APCs. In contrast to freshly isolated PMNp,
which were completely unable to induce a primary MLR
response even at high stimulator cell numbers, PMNp cul-
tured with GM-CSF plus IL-4 and TNF-a were potent
stimulators of allogeneic (Fig. 7 A) as well as autologous T
cells (Fig. 7 C). In terms of their allostimulatory capacity,
PMNp cultured with GM-CSF plus IL-4 plus TNF-a are
virtually identical with monocyte-derived DCs (Fig. 7 B).
Activation of these PMNp-derived DCs with CD40L even
further enhances their stimulatory capacity (Fig. 7 B). The
results of soluble antigen presentation experiments were
also particularly striking. PMNp after cultivation were at
least 10,000 times more efficient in presenting soluble anti-
gen (TT) to autologous T cells in comparison with freshly
isolated autologous monocytes (Fig. 7 D)
In parallel to these molecular and functional changes
during culture, significant morphological alterations were
also evident. PMNp cultured with GM-CSF plus IL-4 plus
TNF-a uniformly enlarged and developed relative to the
cytoplasmic proportion, small nonlobulated round nuclei.
The irregular shaped cells imposed with widespread cyto-
plasmic projections giving the cells a DC-like appearance.
As previously observed in monocyte-derived DCs (8, 11),
cultured neutrophils showed few tendencies to adhere to
the culture plate and formed only a few aggregates. In con-
trast, CD40 activation induced extensive aggregate forma-
tion, enhanced adhesiveness to plastic, and a remarkable in-
crease of dendrite development (Fig. 1 C). A characteristic
feature of most cultivated PMNp, not seen before in other
in vitro DC differentiation systems, are numerous fine cy-
toplasmic inclusions (Fig. 1, G and H). They may represent
residual granule structures as indicated also by the observed
residual expression of the granule marker molecules MPO
and LF.
When taken together, the presented molecular, func-
tional, and morphological findings clearly demonstrate that
neutrophil granulocytes have, even at a late stage of matu-
ration, not only maintained the capacity to synthesize and
express antigen-presenting MHC class II molecules (33,
34), but can be reprogrammed to acquire virtually all the
critical features of DCs.
Such a transition from neutrophil-committed granulo-
cytes to potent APCs is particularly surprising. Neutrophil
granulocytes were for a long time thought to fulfill their
role as host defense via phagocytosis and release of cyto-
toxic compounds, but not to actively synthesize proteins or
to interact with the T cell system. Recently it was shown
that neutrophil granulocytes can synthesize and release im-
munoregulatory cytokines (37) and can be induced to ex-
press MHC class II molecules (33, 34). Our observation
that neutrophil granulocytes at very advanced stages of
maturation can still be shifted in their developmental pro-
gram and can be induced to acquire the molecular, func-
tional, and morphological characteristics of DCs, adds to
those previous findings a new dimension.
Whether such transition to DC-like cells might, in prin-
ciple and with better culture conditions, also be possible
with fully mature PMNs cannot be said at the moment.
Similar to other investigators (38, 39), we were unable to
keep end-stage PMNs viable for prolonged periods of time
in culture. This precluded us from studying the differentia-
tion potential of PMNs with scrutiny. In a few preliminary
experiments we observed, however, induction of MHC
class II expression, as previously reported (33, 34) and also
weak CD40 expression (data not shown). This might indi-
cate that also fully mature PMNs could potentially be
driven to acquire DC characteristics provided that better
PMN culture conditions were available. One caveat clearly
is, however, that also the in vivo half-life of PMNs is rela-
tively short (1 to 2 d; reference 19) and may not allow sub-
stantial alterations of the functional program. Circulating
PMNp regularly seen in inflammatory conditions would,
therefore, seem to be more likely candidates for such pro-
cesses to occur.
Concerning the question as to whether neutrophil-com-
mitted cells can also in vivo be induced to acquire DC
characteristics, we can only speculate. At least in principle,
the cytokines used in our in vitro differentiation system
should be present at inflammatory sites where monocytes/
macrophages, T cells, and potentially mast cells are also
accumulating (40–42). Whether these cytokines also quan-
titatively reach similar levels as used by us in our in vitro
system remains, however, to be shown. On the other hand,
one also has to envisage that counteractive forces not
present in our culture medium may come into action in
vivo, which may inhibit DC development. Perhaps of rele-
vance in this respect, are putative differentiation inhibitory
factors present in human serum (43–45). A further limita-
tion might be the time period required for DC develop-
ment from neutrophil granulocytes, which is 6–8 d in our
culture system. This clearly exceeds the life time of tissue
infiltrating end-stage PMNs (19, 30), but not necessarily so
for more immature neutrophils including band cells and
metamyelocytes accumulating in blood and tissue in in-
flammatory disease states (30). During these infection epi-
sodes, cytokines are likely to be released that are also
present in our culture system.
Independent of these considerations concerning a poten-
tial in vivo role, our finding that neutrophils at a late stage1027 Oehler et al.
of maturation that are virtually lacking any T cell activating
property can, under defined conditions, be driven to ac-
quire the characteristics of professional APCs with potent T
cell immunostimulatory capacity, is also of general interest.
It clearly demonstrates, that neutrophil commitment is not
as irreversible as one has so far been inclined to believe. It,
in addition, offers the opportunity to study the molecular
basis of (sub)lineage differentiation control. With its two
extremes in functional behavior, this model may further
help us in the future to gain better insight into the molecu-
lar processes involved in the development and regulation of
accessory cell function.
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